<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01462227</url>
  </required_header>
  <id_info>
    <org_study_id>HIC1006006927</org_study_id>
    <nct_id>NCT01462227</nct_id>
  </id_info>
  <brief_title>Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia</brief_title>
  <official_title>The Effect of Opiate Blockade With Naltrexone on Counterregulatory Mechanisms in Hypoglycemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Insulin treatment often causes the blood glucose levels to fall too low. The body usually
      responds to low blood glucose levels by releasing hormones which act against the insulin to
      help correct the low blood glucose levels. However, this hormone response can be altered in
      people with diabetes. Currently there are no therapeutic agents that can be used to improve
      the recovery from hypoglycemia (low blood sugar). Naltrexone is a tablet used to help people
      who are addicted to alcohol or morphine-based drugs to remain drug and alcohol-free but it
      can also affect the levels of the hormones which are released during hypoglycemia. The aim of
      this study is to determine whether naltrexone can be used to improve and accelerate the
      recovery from hypoglycemia in patients with type 1 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose (mg/dL)</measure>
    <time_frame>End of study (up to 240 minutes)</time_frame>
    <description>Glucose was measured in the blood throughout the hyperinsulinemic-hypoglycemic clamp study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose Infusion Rate (mg/kg.Min)</measure>
    <time_frame>End of study (up to 240 minutes)</time_frame>
    <description>The glucose infusion rate corresponds to the amount of 20% dextrose given during the hyperinsulinemic-hypoglycemic clamp study, necessary to keep blood glucose levels at the target range (50-55 mg/dL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucagon (pg/mL)</measure>
    <time_frame>End of study (up to 240 minutes)</time_frame>
    <description>Glucagon was measured in the blood throughout the hyperinsulinemic-hypoglycemic clamp study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortisol (ug/dL)</measure>
    <time_frame>End of study (up to 240 minutes)</time_frame>
    <description>Cortisol was measured in the blood throughout the hyperinsulinemic-hypoglycemic clamp study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epinephrine (pg/mL)</measure>
    <time_frame>End of study (up to 240 minutes)</time_frame>
    <description>Epinephrine was measured in the blood throughout the hyperinsulinemic-hypoglycemic clamp study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Norepinephrine (pg/mL)</measure>
    <time_frame>End of study (up to 240 minutes)</time_frame>
    <description>Norepinephrine was measured in the blood throughout the hyperinsulinemic-hypoglycemic clamp study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>Naltrexone (higher dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naltrexone 100mg tablets were randomly given on 1 of 2 occassions (the other was placebo). The drug was administered 12 hours and 1 hour orally pre-procedure to participants. Placebo was given to the high dose group on 1 of their 2 visits- the order in which placebo was given was randomized by dosage arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naltrexone (lower dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naltrexone 50mg tablets were randomly given on 1 of 2 occassions (the other was placebo). The drug was administered 12 hours and 1 hour orally pre-procedure to participants. Placebo was given to the low dose group on 1 of their 2 visits- the order in which placebo was given was randomized by dosage arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone High Dose</intervention_name>
    <description>Naltrexone 100mg for two administrations.</description>
    <arm_group_label>Naltrexone (higher dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone Low Dose</intervention_name>
    <description>Naltrexone 50mg for two administrations.</description>
    <arm_group_label>Naltrexone (lower dose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 1 diabetes (well controlled, 2-3 hypoglycemic episodes/wk) age 18-55, BMI 18-35

        Exclusion Criteria:

          -  pregnancy

          -  significant diabetes complications

          -  liver disease, cirrhosis

          -  cardiac disease

          -  neurological disorder

          -  autonomic neuropathy

          -  kidney disease

          -  lactose intolerance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Sherwin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2011</study_first_submitted>
  <study_first_submitted_qc>October 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2011</study_first_posted>
  <results_first_submitted>January 20, 2016</results_first_submitted>
  <results_first_submitted_qc>February 17, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 18, 2016</results_first_posted>
  <last_update_submitted>February 17, 2016</last_update_submitted>
  <last_update_submitted_qc>February 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypoglycemia</keyword>
  <keyword>Type 1 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Naltrexone (Lower Dose) First /Placebo Second</title>
          <description>Naltrexone 50 mg, 1 tablet given 12 hours prior to visit orally Placebo given at time of visit orally</description>
        </group>
        <group group_id="P2">
          <title>Placebo First/ Naltrexone (Lower Dose) Second</title>
          <description>Placebo given given 12 hours prior to visit orally Naltrexone 50 mg (1 tablet) given at time of visit orally</description>
        </group>
        <group group_id="P3">
          <title>Naltrexone (Higher Dose) First /Placebo Second</title>
          <description>Naltrexone 100 mg, 1 tablet given 12 hours prior to visit orally Placebo given at time of visit orally</description>
        </group>
        <group group_id="P4">
          <title>Placebo First / Naltrexone (Higher Dose) Second</title>
          <description>Placebo given 12 hours prior to visit orally Naltrexone 100 mg (1 tablet) given at time of visit orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Assignment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Assignment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline population includes subjects that completed study</population>
      <group_list>
        <group group_id="B1">
          <title>Naltrexone (Lower Dose)</title>
          <description>Naltrexone: Naltrexone 50 mg, 1 tablet given every 12 hours orally</description>
        </group>
        <group group_id="B2">
          <title>Naltrexone (Higher Dose)</title>
          <description>Naltrexone: Naltrexone 100mg, 1 tablet given every 12 hours orally</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.3" spread="11"/>
                    <measurement group_id="B2" value="32.4" spread="12"/>
                    <measurement group_id="B3" value="32.4" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Glucose (mg/dL)</title>
        <description>Glucose was measured in the blood throughout the hyperinsulinemic-hypoglycemic clamp study.</description>
        <time_frame>End of study (up to 240 minutes)</time_frame>
        <population>Subjects' data were pooled and only those that completed both visits are analyzed here.</population>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone (Lower Dose)</title>
            <description>Subjects were randomized to receive either Naltrexone 50 mg or placebo: 1 tablet given 12 hours prior to visit orally and again at time of visit.</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone (Higher Dose)</title>
            <description>Subjects were randomized to receive either Naltrexone 100 mg or placebo: 1 tablet given 12 hours prior to visit orally and again at time of visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose (mg/dL)</title>
          <description>Glucose was measured in the blood throughout the hyperinsulinemic-hypoglycemic clamp study.</description>
          <population>Subjects' data were pooled and only those that completed both visits are analyzed here.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Active Drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.5" spread="3.7"/>
                    <measurement group_id="O2" value="52.8" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0" spread="2.8"/>
                    <measurement group_id="O2" value="52.8" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Glucose Infusion Rate (mg/kg.Min)</title>
        <description>The glucose infusion rate corresponds to the amount of 20% dextrose given during the hyperinsulinemic-hypoglycemic clamp study, necessary to keep blood glucose levels at the target range (50-55 mg/dL).</description>
        <time_frame>End of study (up to 240 minutes)</time_frame>
        <population>Subjects' data were pooled and only those that completed both visits are analyzed here.</population>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone (Lower Dose)</title>
            <description>Subjects were randomized to receive either Naltrexone 50 mg or placebo: 1 tablet given 12 hours prior to visit orally and again at time of visit.</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone (Higher Dose)</title>
            <description>Subjects were randomized to receive either Naltrexone 100 mg or placebo: 1 tablet given 12 hours prior to visit orally and again at time of visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Infusion Rate (mg/kg.Min)</title>
          <description>The glucose infusion rate corresponds to the amount of 20% dextrose given during the hyperinsulinemic-hypoglycemic clamp study, necessary to keep blood glucose levels at the target range (50-55 mg/dL).</description>
          <population>Subjects' data were pooled and only those that completed both visits are analyzed here.</population>
          <units>mg/kg.min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Active Drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="2.7"/>
                    <measurement group_id="O2" value="6.3" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="4.0"/>
                    <measurement group_id="O2" value="5.9" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucagon (pg/mL)</title>
        <description>Glucagon was measured in the blood throughout the hyperinsulinemic-hypoglycemic clamp study.</description>
        <time_frame>End of study (up to 240 minutes)</time_frame>
        <population>Subjects' data were pooled and only those that completed both visits are analyzed here.</population>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone (Lower Dose)</title>
            <description>Subjects were randomized to receive either Naltrexone 50 mg or placebo: 1 tablet given 12 hours prior to visit orally and again at time of visit.</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone (Higher Dose)</title>
            <description>Subjects were randomized to receive either Naltrexone 100 mg or placebo: 1 tablet given 12 hours prior to visit orally and again at time of visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Glucagon (pg/mL)</title>
          <description>Glucagon was measured in the blood throughout the hyperinsulinemic-hypoglycemic clamp study.</description>
          <population>Subjects' data were pooled and only those that completed both visits are analyzed here.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Active Drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.1" spread="17.4"/>
                    <measurement group_id="O2" value="48.9" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4" spread="7.9"/>
                    <measurement group_id="O2" value="53.6" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cortisol (ug/dL)</title>
        <description>Cortisol was measured in the blood throughout the hyperinsulinemic-hypoglycemic clamp study.</description>
        <time_frame>End of study (up to 240 minutes)</time_frame>
        <population>Subjects' data were pooled and only those that completed both visits are analyzed here.</population>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone (Lower Dose)</title>
            <description>Subjects were randomized to receive either Naltrexone 50 mg or placebo: 1 tablet given 12 hours prior to visit orally and again at time of visit.</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone (Higher Dose)</title>
            <description>Subjects were randomized to receive either Naltrexone 100 mg or placebo: 1 tablet given 12 hours prior to visit orally and again at time of visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Cortisol (ug/dL)</title>
          <description>Cortisol was measured in the blood throughout the hyperinsulinemic-hypoglycemic clamp study.</description>
          <population>Subjects' data were pooled and only those that completed both visits are analyzed here.</population>
          <units>ug/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Active Drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9" spread="8.3"/>
                    <measurement group_id="O2" value="16.4" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" spread="7.0"/>
                    <measurement group_id="O2" value="15.2" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Epinephrine (pg/mL)</title>
        <description>Epinephrine was measured in the blood throughout the hyperinsulinemic-hypoglycemic clamp study.</description>
        <time_frame>End of study (up to 240 minutes)</time_frame>
        <population>Subjects' data were pooled and only those that completed both visits are analyzed here.</population>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone (Lower Dose)</title>
            <description>Subjects were randomized to receive either Naltrexone 50 mg or placebo: 1 tablet given 12 hours prior to visit orally and again at time of visit.</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone (Higher Dose)</title>
            <description>Subjects were randomized to receive either Naltrexone 100 mg or placebo: 1 tablet given 12 hours prior to visit orally and again at time of visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Epinephrine (pg/mL)</title>
          <description>Epinephrine was measured in the blood throughout the hyperinsulinemic-hypoglycemic clamp study.</description>
          <population>Subjects' data were pooled and only those that completed both visits are analyzed here.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Active Drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.75" spread="30.6"/>
                    <measurement group_id="O2" value="126.1" spread="98.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.75" spread="23.1"/>
                    <measurement group_id="O2" value="77.9" spread="65.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Norepinephrine (pg/mL)</title>
        <description>Norepinephrine was measured in the blood throughout the hyperinsulinemic-hypoglycemic clamp study.</description>
        <time_frame>End of study (up to 240 minutes)</time_frame>
        <population>Subjects' data were pooled and only those that completed both visits are analyzed here.</population>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone (Lower Dose)</title>
            <description>Subjects were randomized to receive either Naltrexone 50 mg or placebo: 1 tablet given 12 hours prior to visit orally and again at time of visit.</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone (Higher Dose)</title>
            <description>Subjects were randomized to receive either Naltrexone 100 mg or placebo: 1 tablet given 12 hours prior to visit orally and again at time of visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Norepinephrine (pg/mL)</title>
          <description>Norepinephrine was measured in the blood throughout the hyperinsulinemic-hypoglycemic clamp study.</description>
          <population>Subjects' data were pooled and only those that completed both visits are analyzed here.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Active Drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="248.3" spread="80.2"/>
                    <measurement group_id="O2" value="200.1" spread="77.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="282.8" spread="97.3"/>
                    <measurement group_id="O2" value="217.1" spread="91.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>End of study, up to 240 minutes.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Naltrexone (50 mg)</title>
          <description>Naltrexone 50 mg, 1 tablet given 12 hours and again at 1 hour prior to testing (orally).</description>
        </group>
        <group group_id="E2">
          <title>Placebo (Lower Dose Group)</title>
          <description>Placebo 1 tablet given 12 hours and again at 1 hour prior to testing (orally).</description>
        </group>
        <group group_id="E3">
          <title>Naltrexone (100 mg)</title>
          <description>Naltrexone 100 mg, 1 tablet given 12 hours and again at 1 hour prior to testing (orally).</description>
        </group>
        <group group_id="E4">
          <title>Placebo (Higher Dose)</title>
          <description>Placebo 1 tablet given 12 hours and again at 1 hour prior to testing (orally).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Stanley Sherwin, MD</name_or_title>
      <organization>Yale University</organization>
      <phone>203 737 1932</phone>
      <email>robert.sherwin@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

